Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 6;5(10):e640. doi: 10.1097/HS9.0000000000000640

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 6. — Overall survival in PTLD based on EFS24 status. (A) Kaplan Meier estimates for PTLD patients achieving EFS24 compared with US general population with PTLD and de novo (non-PTLD) DLBCL. Red: Expected survival (general US population) for PTLD; Green: Monomorphic DLBCL, PTLD achieving EFS24; Blue: De novo (non-PTLD) DLBCL achieving EFS24. (B) Overall survival from early event within 24 months of diagnosis in cohort who failed EFS24. Red: Expected survival (general US population) for PTLD, Green: Monomorphic DLBCL PTLD not achieving EFS24, Blue: De novo (non-PTLD) DLBCL not achieving EFS24. DLBCL = diffuse large B cell lymphoma; EFS, event-free survival; PTLD = post-transplant lymphoproliferative disorder.